Ocumension Therapeutics
01477
Company Profile
Business description
Ocumension Therapeutics is an ophthalmic pharmaceutical platform company identifying, developing, and commercializing ophthalmic therapies. It provides a pharmaceutical total solution to address unmet ophthalmic medical needs in China. Its product candidates include OT-401 (YUTIQ), OT-101, OT-301 (NCX 470), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-202, OT-503 (NCX 4251), OT-701, Ou Qin, Brimonidine tartrate eye drop, 0.5% moxifloxacin eye drop, OT-601-C, OT-302, OT-1301, T-1601, and OT-1602.
Contact
No. 1858 Yinzhongnan Road
Guoxiang Subdistrict
Wuzhong District
SuzhouJiangsu
CHNT: +86 2161493800
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
489
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,777.50 | 6.90 | 0.08% |
| CAC 40 | 7,684.68 | 80.43 | -1.04% |
| DAX 40 | 23,516.23 | 255.22 | -1.07% |
| Dow JONES (US) | 42,197.79 | 769.83 | -1.79% |
| FTSE 100 | 8,850.63 | 34.29 | -0.39% |
| HKSE | 23,883.87 | 8.69 | -0.04% |
| NASDAQ | 19,406.83 | 255.66 | -1.30% |
| Nikkei 225 | 38,193.39 | 359.14 | 0.95% |
| NZX 50 Index | 12,618.98 | 66.11 | 0.53% |
| S&P 500 | 5,976.97 | 68.29 | -1.13% |
| S&P/ASX 200 | 8,551.80 | 4.40 | 0.05% |
| SSE Composite Index | 3,379.96 | 2.96 | 0.09% |